respiratory-syncytial-virus

Documents about respiratory-syncytial-virus

• Observational Program to Assess Respiratory Syncytial Virus (RSV) Hospitalization Rate in Population of Children at High-risk of Serious RSV Illness Who Received Palivizumab Immunoprophylaxis#917876ClinicalTrials.gov
• Effect of Respiratory Virus Infection on EmeRgencY Admission Study (EVERY Study)#1009297ClinicalTrials.gov
• A Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus (RSV) When Given Alone and Together With a COVID-19 mRNA Vaccine in Adults Aged 50 Years and Above#1008766ClinicalTrials.gov
• Pharmacokinetics and Safety of RV521 Formulations#892045ClinicalTrials.gov
• RV568 - Viral Challenge With RSV#992686ClinicalTrials.gov
• Phase I, First-In Human Study to Evaluate Safety and Tolerability of EuRSV in Healthy Adults Aged Between 19 Years and 80 Years#160168ClinicalTrials.gov
• Study of Safety, Reactogenicity and Immunogenicity of GlaxoSmithKline's (GSK)Respiratory Syncytial Virus (RSV)Maternal Unadjuvanted Vaccine in Healthy Pregnant Women (Aged 18 to 40 Years) and Their Infants#683050ClinicalTrials.gov
• An Observational Study to Assess Respiratory Syncytial Virus (RSV) Respiratory Events Among Premature Infants#828859ClinicalTrials.gov
• A Study to Evaluate the Safety and Efficacy of MEDI8897 for the Prevention of Medically Attended RSV LRTI in Healthy Preterm Infants.#806321ClinicalTrials.gov
• Respiratory syncytial virus (RSV) in older adults: from infection to outcomes – who gets sick, who gets hospitalized, who survives?#315050HAL (France)
• Inpatient Challenge Study of rRSV A/Maryland/001/11, a Human Respiratory Syncytial Virus Challenge Strain, Administered to Healthy Adult Volunteers#831797ClinicalTrials.gov
• Immunogenicity of RSVPreF3 Vaccine in Immunocompromised Persons#448319ClinicalTrials.gov
• A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ≥50 Years of Age#857668ClinicalTrials.gov
• Phase 2a Respiratory Syncytial Virus (RSV) Human Challenge Study of Clesrovimab (MK-1654) in Healthy Participants (MK-1654-005)#803712ClinicalTrials.gov
• A Study to Assess the Pharmacokinetics, Safety, and Tolerability of Multiple Doses of Orally Administered JNJ-53718678 in Infants Hospitalized With Respiratory Syncytial Virus (RSV) Infection#884414ClinicalTrials.gov
• A Study to Rank Different Dosages of Antigen of GlaxoSmithKline (GSK) Biologicals' Investigational Respiratory Syncytial Virus (RSV) Vaccine (GSK3003891A), Based on Their Immune Response and Safety, When Administered to Healthy Adult Women#208295ClinicalTrials.gov
• Evaluating the Safety and Immune Response to a Single Dose of a Respiratory Syncytial Virus (RSV) Vaccine in RSV-Seronegative Infants and Children#810090ClinicalTrials.gov
• A Dose Finding Study of VN-0200#878447ClinicalTrials.gov
• Modélisation des dynamiques de co-infections entre virus respiratoires dans l’épithélium respiratoire humain reconstitué#235168HAL (France)
• Cost-effectiveness of strategies using preventive interventions to protect infants in Chile from respiratory syncytial virus#637321Repositorio Universidad del Desarrollo
• Evaluation of RSV/Flu-01E Vaccine for the Prevention of RSV Infection in Volunteers Aged 18 to 59 Years and Over 60 Years#880567ClinicalTrials.gov
• A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Safety of MEDI-559 in Healthy 1 to <24 Month-Old Children#894477ClinicalTrials.gov
• A Phase 2a Study to Evaluate ALS-008176 in the Virus Challenge Model#853553ClinicalTrials.gov
• Novel strategies to enhance vaccine immunity in neonatal livestock#464212HAL (France)
• Respiratorische Synzytialvirusfälle in Deutschland#14618DataCite
• Respiratorische Synzytialvirusfälle in Deutschland#124811DataCite
• RSV-MVA-BN Vaccine Phase I Trial, Intranasal Application in Adults.#383612ClinicalTrials.gov
• Systems Biological Analysis of Immune Responses to RSV Vaccine#860262ClinicalTrials.gov
• A Study Evaluating Persistence of the Immune Response of the Adjuvanted Respiratory Syncytial Virus (RSV) Vaccine and the Safety and Immune Response Following Revaccination in Adults 18 Years of Age and Above Who Received Lung or Kidney Transplant#181613ClinicalTrials.gov
• Clinical and epidemiological changes in severe viral respiratory infections in pediatric patients after the COVID-19 pandemic in Spain.#672221Repisalud
• Maternal RSVpreF Vaccine Effectiveness Against Respiratory Syncytial Virus in Hospitalized Infants.#469438NCBI PubMed Central
• Evaluating the Benefits of RSV Maternal Vaccination Using a Scottish National Dataset#838433ClinicalTrials.gov
• Acute viral bronchiolitis : dawn of a new era for the prevention of respiratory syncytial virus infection through vaccination#345976University of Pretoria Repository
• Is Clinical Outcome Pathogen Related? Characteristics and Outcomes of ICU Patients with Severe Acute Respiratory Infections: Focusing on Respiratory Syncytial Virus, Human Metapneumovirus, Influenza Virus, and Parainfluenza Virus.#171996NCBI PubMed Central
• Immunogenicity of RSV Vaccines in Residents of Long-Term Care Facilities (LTCF)#195376ClinicalTrials.gov
• Nirsevimab vs RSVpreF Vaccine for Respiratory Syncytial Virus-Related Hospitalization in Newborns.#301702NCBI PubMed Central
• A Study of BLB-201 RSV Vaccine in Infants and Children#366643ClinicalTrials.gov
• Double-Stapled Peptide Scan Yields Potent Fusion Inhibitors of Respiratory Syncytial Virus#411860HAL (France)
• Extension Study to Evaluate the Safety and Immunogenicity of a Revaccination Dose of the RSVPreF3 OA Investigational Vaccine in Adults 60 Years and Older Who Participated in the RSV OA=ADJ-002 Study#810861ClinicalTrials.gov
• Comparison of Nylon Flocked Swabs and Saline Aspirates for Detection Respiratory Viruses#849536ClinicalTrials.gov
• A Study to Evaluate a Single Intramuscular Dose of Motavizumab to Treat Children With Respiratory Syncytial Virus (RSV) Illness#805555ClinicalTrials.gov
• Intermittent Use of Aerosolized Ribavirin for Treatment of RSV#860775ClinicalTrials.gov
• A Study to Learn About the Vaccine RSVpreF In Pregnant Participants With HIV and Their Infants#180184ClinicalTrials.gov
• A Study to Assess the Safety, Tolerability, and Immunogenicity of RSVpreF in Older Adults in Korea#321540ClinicalTrials.gov
• Cost-effectiveness of respiratory syncytial virus vaccination for older adults: a modelling analysis#444935bioRxiv / medRxiv
• Safety and Tolerability Study to Evaluate MEDI-534 in Children 6 to < 24 Months of Age#878885ClinicalTrials.gov
• A Study of an Ad26.RSV.preF-based Regimen in the Prevention of Reverse Transcriptase Polymerase Chain Reaction (RT-PCR)-Confirmed Respiratory Syncytial Virus (RSV)-Mediated Lower Respiratory Tract Disease in Adults Aged 65 Years and Older#172384ClinicalTrials.gov
• Recent trends in hospitalizations for respiratory syncytial virus after the COVID-19 pandemic and before routine immunization: Seasonality and severity updates from the 2023/2024 season in Tuscany, Italy#254344IRIS
• A Study to Learn About Two or More Vaccines That Are Put Together as One Shot Against Infectious Lung Illnesses, Including COVID-19 and Respiratory Syncytial Virus (RSV).#902910ClinicalTrials.gov
• Phase 1 Study of BLB-201 Vaccine in Healthy Young and Older Adults#287396ClinicalTrials.gov